Accessibility Menu
Medexus Pharmaceuticals logo

Medexus Pharmaceuticals(OTC) MEDXF

Market Cap$116.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+1%
5 Year+15%
1 Year+69%
1 Month+4%
$3.72
+2.54%
+0.09Today
Medexus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 3.722026-08-31
Medexus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.64%USD 3.662026-08-24
1 month+4.38%USD 3.562026-07-31
3 month+31.77%USD 2.822026-06-02
Year to date+76.63%USD 2.112025-12-31
1 year+69.09%USD 2.202025-08-29
3 year+73.83%USD 2.142023-09-01
5 year+14.64%USD 3.252021-09-01
Since inception+0.53%USD 3.702017-11-27

Medexus Pharmaceuticals Financials at a Glance

Market Cap

$116.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$102.58M

Net Income (TTM)

-$2.38M

EPS (TTM)

-$0.07

P/E Ratio

-50.47

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$3.72

Volume

13,700

Open

$3.74

Previous Close

$3.72

Daily Range

$3.72 - $3.74

52-Week Range

$1.80 - $3.96

Estimated Earnings Date

Nov 11, 2026

MEDXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. is a specialized pharmaceutical firm operating in Canada and the United States. The company focuses on critical therapeutic areas, including oncology, hematology, rheumatology, autoimmune disorders, and allergies.

Products and Services
  • Rasuvo and Metoject for rheumatoid arthritis management
  • IXINITY, a therapy for Hemophilia B
  • Rupall, a prescription medication for allergies
Growth Outlook
  • Recent quarterly revenue reached $27.86 million, a significant increase
  • Gross profit margin improved to 55.39% in the latest quarter
  • Strong product pipeline supports future revenue growth potential
Financial Highlights
  • Trailing twelve months revenue of $99.5 million, showing upward trend
  • Net income of $530,185 reported in the latest quarter
  • Operating income margin of 7.40% indicates operational efficiency
Medexus Pharmaceuticals Inc. has established itself as a key player in the pharmaceutical industry, focusing on innovative treatments for various medical conditions. The company's diverse product offerings, including specialized therapies for autoimmune disorders and blood disorders, position it well for future growth. Recent financial performance highlights a positive trajectory, with increasing revenue and improving profit margins. The strong product pipeline and operational efficiency further enhance the company's potential for sustained growth, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

90

CEO

Kenneth d’Entremont

Website

www.medexus.com

Headquarters

Toronto, ON M5C 1C3, CA

MEDXF Financials

Key Financial Metrics (TTM)

Gross Margin

54.66%

Operating Margin

6.62%

Net Income Margin

-2.32%

Return on Equity

-4.72%

Return on Capital

8.19%

Return on Assets

-1.68%

Earnings Yield

-1.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$116.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.43M

Volume

13.70K

Avg. Volume

15.25K

Financials (TTM)

Gross Profit

$56.07M

Operating Income

$7.05M

EBITDA

$12.63M

Operating Cash Flow

$13.84M

Capital Expenditure

-$15.05M

Free Cash Flow

-$1.21M

Cash & ST Invst.

$5.34M

Total Debt

$26.22M

Medexus Pharmaceuticals Performance Analysis

Medexus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 108,096,00040.9%
20242024-03-31USD 113,054,0004.6%
20252025-03-31USD 108,332,000-4.2%
20262026-03-31USD 99,332,000-8.3%
Medexus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-300.5%
Q32025-12-312.4%
Q42026-03-31-2.7%
Q12026-06-3013.0%
Medexus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD 0.06N/A
20242024-03-31USD -0.01N/A
20252025-03-31USD 0.08N/A
20262026-03-31USD -0.07N/A
Medexus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-159.3%
Q32025-12-31126.0%
Q42026-03-31-3396.0%
Q12026-06-30120.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$27.86M

+13.2%

Gross Profit

$15.43M

+12.0%

Gross Margin

55.39%

N/A

Market Cap

$116.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

90

N/A

Net Income

$530.19K

+2.7%

EBITDA

$4.41M

-0.8%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$5.34M

-42.8%

Total Debt

$26.22M

+19.8%

Accounts Receivable

$13.08M

+5.8%

Inventory

$29.83M

-15.7%

Long Term Debt

$23.83M

+14888.9%

Short Term Debt

$2.39M

-89.0%

Return on Assets

-1.68%

N/A

Return on Invested Capital

7.02%

N/A

Free Cash Flow

-$1.14M

-130.0%

Operating Cash Flow

-$1.12M

-128.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VEXTFVext Science, Inc.
$0.20-1.48%
PLNHPlanet 13 Holdings Inc.
$0.13+3.08%
INISRadnostix, Inc.
$0.06+0.00%
ETSTEarth Science Tech, Inc.
$0.09+4.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About MEDXF

What is the current price of Medexus Pharmaceuticals?

Medexus Pharmaceuticals is trading at $3.72 per share.

What is the 52-week range for Medexus Pharmaceuticals?

Over the past 52 weeks, Medexus Pharmaceuticals has traded between $1.80 and $3.96.

How much debt does Medexus Pharmaceuticals have?

As of the most recent reporting period, Medexus Pharmaceuticals reported total debt of $26.25M.

How much cash does Medexus Pharmaceuticals have on hand?

Medexus Pharmaceuticals reported $5.34M in cash and cash equivalents in its most recent financial results.

What is Medexus Pharmaceuticals’s dividend yield?

Medexus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services